Clinical Trials · NCT06737042
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Gan and Lee Pharmaceuticals, USA
- Enrollment
- 285
- Start date
- Feb 2025
- Locations
- 20 sites, United States
- Primary endpoint
- Primary Objective